Feasibility of Study of Empagliflozin in Patients With Autosomal Dominant Polycystic Kidney Disease

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

November 18, 2022

Primary Completion Date

March 31, 2026

Study Completion Date

March 31, 2026

Conditions
Polycystic Kidney, Autosomal Dominant
Interventions
DRUG

Empagliflozin

Empagliflozin: The chemical name of empagliflozin is D-Glucitol,1,5-anhydro-1-C-\[4-chloro-3-\[\[4-\[\[(3S)-tetrahydro-3furanyl\]oxy\]phenyl\]methyl\]phenyl\]-, (1S). Empagliflozin is a white to yellowish, non-hygroscopic powder. It is very slightly soluble in water, sparingly soluble in methanol, slightly soluble in ethanol and acetonitrile; soluble in 50% acetonitrile/water; and practically insoluble in toluene. Empagliflozin power will be added in white and bovine origin gelatin capsules. Each capsule of empagliflozin will contain 10 mg or 25 mg of empagliflozin (free base) and the following inactive ingredients: microcrystalline cellulose magnesium, stearate, dicalcium phosphate, and silicone dioxide.

DRUG

Placebo

Placebo capsules will be matched in size and color to empagliflozin capsules. Each placebo capsule will contain the following inactive ingredients: microcrystalline cellulose magnesium, stearate, dicalcium phosphate, and silicone dioxide.

Trial Locations (1)

80045

University of Coloardo Anschutz Medical Campus, Aurora

All Listed Sponsors
collaborator

University of Maryland

OTHER

lead

University of Colorado, Denver

OTHER